New male pattern baldness candidates turned up in an analysis of more than 70,000 individuals, including UK Biobank participants profiled for a prior baldness GWAS.
The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
With the rollout of Insitome's first app, consumers have the chance to explore their heritage in a new context that could reshape the ancestry testing market.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The OncoArray Consortium researchers also uncovered a new candidate susceptibility gene for low-grade and borderline serous epithelial ovarian cancer.
Scotland's Arrayjet will provide the Bronx-based NYBC with microarray instrumentation, printing, and expertise under an approximately $250,000 contract.
The company announced the new product, which covers variants across 600 genes, this week, and said it will be available to customers next month.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.